Results published demonstrating accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging
Zurich-Schlieren, Switzerland, March 9, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new results evaluating Proclarix® in combination with imaging were published in BJU International[1].
The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging (mpMRI) has been a significant advance in prostate cancer diagnosis and is recommended in most current guidelines. Proclarix® is a blood-based biomarker test aiding in the identification of prostate cancer.
The aim of the study highlighted here was the assessment of the diagnostic performance of Proclarix in combination with mpMRI. Blood samples from 721 men undergoing mpMRI followed by biopsy at University College London (UCL), London, and Vall d’Hebron University Hospital, Barcelona were analyzed.
The combined Proclarix-MRI score’s specificity (68%) was significantly (p<0.001) better compared to Proclarix (27%) or mpMRI (28%) alone. In addition, Proclarix by itself was found to be useful in men with indetermined imaging results (the MRI PI-RADS 3 subgroup) by outperforming PSA density in terms of specificity (25% vs 13%, p=0.004) at 100% sensitivity.
”Proclarix in combination with mpMRI reliably predicted clinically significant prostate cancer and ruled out men with no or indolent cancer. A large reduction of two thirds of unneeded biopsies was achieved” Prof. Mark Emberton from UCL commented and further added: ”Combining imaging with biomarkers such as Proclarix is clearly the future in terms of prostate cancer risk stratification.”
BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. For more than ninety years, it has provided invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles across the field of urology.